To this end, we utilized a pharmacogenomics analysis of KRAS-mutant CRC cell lines with differing sensitivity to pharmacologic MEK inhibition and identified transcriptional states associated with resistance. The gene discussed is KRAS; the disease is colorectal carcinoma.